There's no reliable evidence that an infusion of blood plasma from a young donor will benefit an older person, and there are risks, but Ambrosia Health is selling "young blood" infusions for thousands of dollars anyway. The FDA has taken notice.
The Food and Drug Administration just won a court case supporting the agency's ability to regulate stem cell clinics that rely on client-derived adipose tissues. This is a win for consumer protection, though too late to help those already harmed.
A lawsuit claiming Walmart fraudulently deceives consumers in the sale of worthless homeopathic remedies has been filed by the Center for Inquiry (CFI), acting on behalf of the general public. CFI says co-mingling ineffective homeopathic products with science-based treatments on Walmart's pharmacy shelves and website misleads customers into thinking they are equivalent, when "there is not a shred of credible scientific evidence"...
Drug approval is a process that should be and, for the most part, is rooted in rigorous science. However, there is always a countervailing pressure to approve new drugs rapidly, particularly in cancer. That's why the FDA created the accelerated approval program in the early 1990s. Unfortunately, increasingly this approval process appears to be failing us in oncology. Reform is needed.
The FDA reminds everyone that (no matter what your state says) CBD is not a legal ingredient in dietary supplements and foods. The agency is willing to explore changes to the law but unproven claims for CBD health benefits, such cancer cures, will not be tolerated.
A new FDA rule will require evidence of safety and effectiveness for substances used in compounded drugs, alarming naturopaths and integrative physicians. Experts have recommended that a number of naturopathic compounding favorites be banned.
The FDA promises the "most significant modernization of dietary supplement regulation" in 25 years while maintaining its industry-friendly regulatory scheme.
The Goldwater Institute and the Kochs pushed "right to try" laws in an attempt to get rid of FDA oversight of access to investigational drugs. Instead, they created tremendous legal uncertainties, making the FDA's expanded access program preferable for all.
The stem cell hard sell: The Medical Board of California is forming a task force to determine how to regulate physicians offering stem cell therapies.
For-profit stem cell clinics selling unproven and downright quacky stem cell therapies have proliferated over the last several years, with federal and state law seemingly powerless to stop them. Recently, the FDA and FTC have shown signs of acting to crack down on them. Now, the Medical Board of California is forming a task force to determine how to regulate physicians offering...
An FTC settlement may kill "amniotic stem cell" treatments, but a plethora of other stem cell clinics flourish without regulatory oversight.